<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36617536</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis regional progression intervals change according to time of involvement of different body regions.</ArticleTitle><Pagination><StartPage>872</StartPage><EndPage>880</EndPage><MedlinePgn>872-880</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15674</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">The prediction of disease course is one of the main targets of amyotrophic lateral sclerosis (ALS) research, particularly considering its wide phenotypic heterogeneity. Despite many attempts to classify patients into prognostic categories according to the different spreading patterns at diagnosis, a precise regional progression rate and the time of involvement of each region has yet to be clarified. The aim of our study was to evaluate the functional decline in different body regions according to their time of involvement during disease course.</AbstractText><AbstractText Label="METHODS">In a population-based dataset of ALS patients, we analysed the functional decline in different body regions according to time and order of regional involvement. We calculated the regional progression intervals (RPIs) between initial involvement and severe functional impairment using the ALS Functional Rating Scale revised (ALSFRS-r) subscores for the bulbar, upper limb, lower limb and respiratory/thoracic regions. Time-to-event analyses, adjusted for age, sex, ALSFRS-r pre-slope (&#x394;ALSFRS-R), cognitive status, and mutational status were performed.</AbstractText><AbstractText Label="RESULTS">The duration of RPI differed significantly among ALS phenotypes, with the RPI of the first region involved being significantly longer than the RPIs of regions involved later. Cox proportional hazard models showed that in fact a longer&#xa0;time between disease onset and initial regional involvement was related to a reduced duration of the RPI duration in each different body region (bulbar region: hazard ratio [HR] 1.11, 95% confidence interval [CI] 1.06-1.16, p&#x2009;&lt;&#x2009;0.001; upper limb region: HR 1.16, 95% CI 1.06-1.28, p&#xa0;=&#xa0;0.002; lower limb region: HR 1.11, 95% CI 1.03-1.19, p&#xa0;=&#xa0;0.009; respiratory/thoracic region: HR 1.10, 95% CI 1.06-1.14, p&#xa0;=&#xa0;0.005).</AbstractText><AbstractText Label="CONCLUSIONS">We found that the progression of functional decline accelerates in regions involved later during disease course. Our findings can be useful in patient management and prognosis prediction.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-9995-8133</Identifier><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ovidio</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6304-5415</Identifier><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabras</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrieri</LastName><ForeName>Maria Claudia</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-9312-7497</Identifier><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palumbo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0197-1880</Identifier><AffiliationInfo><Affiliation>ALS Center, Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carit&#xe0;, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALS Center, Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carit&#xe0;, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7377-7222</Identifier><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5122-7243</Identifier><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">disease spreading</Keyword><Keyword MajorTopicYN="N">prion-like mechanism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>8</Day><Hour>23</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36617536</ArticleId><ArticleId IdType="doi">10.1111/ene.15674</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Chi&#xf2; A, Mora G, Moglia C, et al. Secular trends of amyotrophic lateral sclerosis: the Piemonte and Valle d'Aosta register. JAMA Neurol. 2017;74(9):1097-1104.</Citation></Reference><Reference><Citation>Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009;73(10):805-811.</Citation></Reference><Reference><Citation>Agosta F, Gorno-Tempini ML, Pagani E, et al. Longitudinal assessment of grey matter contraction in amyotrophic lateral sclerosis: a tensor-based morphometry study. Amyotroph Lateral Scler. 2009;10(3):168-174.</Citation></Reference><Reference><Citation>Takeda T, Kitagawa K, Arai K. Phenotypic variability and its pathological basis in amyotrophic lateral sclerosis. Neuropathology. 2019;40:40-56. doi:10.1111/neup.12606. Review.</Citation></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999;169(1-2):13-21.</Citation></Reference><Reference><Citation>Franchignoni F, Mandrioli J, Giordano A, Ferro S, ERRALS Group. A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):331-337.</Citation></Reference><Reference><Citation>Manera U, Calvo A, Daviddi M, et al. Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2020;91(3):291-297.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002;59(1):99-103.</Citation></Reference><Reference><Citation>Iazzolino B, Pain D, Peotta L, et al. Validation of the revised classification of cognitive and behavioural impairment in ALS. J Neurol Neurosurg Psychiatry. 2019;90(7):734-739.</Citation></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3-4):153-174.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Mazzini L, et al. Extensive genetics of ALS: a population-based study in Italy. Neurology. 2012;79(19):1983-1989. doi:10.1212/WNL.0b013e3182735d36. Epub 2012 Oct 24.</Citation></Reference><Reference><Citation>Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS progression. J Neurol Sci. 2008;75:69-73.</Citation></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS functional rating scale. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(3-4):279-284.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38-44. doi:10.1136/jnnp-2013-306589. Epub 2013 Dec 13. PMID: 24336810.</Citation></Reference><Reference><Citation>Gordon PH, Cheng B, Salachas F, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257(10):1713-1717.</Citation></Reference><Reference><Citation>Steinbach R, Batyrbekova M, Gaur N, et al. Applying the D50 disease progression model to gray and white matter pathology in amyotrophic lateral sclerosis. NeuroImage Clin. 2020;25:102094. doi:10.1016/j.nicl.2019.102094</Citation></Reference><Reference><Citation>Vasta R, D'Ovidio F, Canosa A, et al. Plateaus in amyotrophic lateral sclerosis progression: results from a population-based cohort. Eur J Neurol. 2020;27(8):1397-1404. doi:10.1111/ene.14287. Epub 2020 May 22. PMID: 32346913.</Citation></Reference><Reference><Citation>van der Kleij LA, Jones AR, Steen IN, et al. Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):442-447.</Citation></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135(Pt 3):847-852. doi:10.1093/brain/awr351. Epub 2012 Jan 23. PMID: 22271664; PMCID: PMC3286327.</Citation></Reference><Reference><Citation>Thakore NJ, Lapin BR, Kinzy TG, Pioro EP. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7-8):483-494.</Citation></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2015;86(1):45-49.</Citation></Reference><Reference><Citation>Kent-Braun JA, Walker CH, Weiner MW, Miller RG. Functional significance of upper and lower motor neuron impairment in amyotrophic lateral sclerosis. Muscle Nerve. 1998;21(6):762-768. doi:10.1002/(sici)1097-4598(199806)21:6&lt;762::aid-mus8&gt;3.0.co;2-5. PMID: 9585330.</Citation></Reference><Reference><Citation>Vasta R, Solero L, Palumbo F, et al. Can amyotrophic lateral sclerosis progression really pause? A cohort study using the medical research council scale. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(5-6):383-389. doi:10.1080/21678421.2021.1961807. Epub 2021 Aug 9. PMID: 34365891.</Citation></Reference><Reference><Citation>Sugaya K, Nakano I. Prognostic role of "prion-like propagation" in SOD1-linked familial ALS: an alternative view. Front Cell Neurosci. 2014;8:359.</Citation></Reference><Reference><Citation>Eisen A, Braak H, Del Tredici K, Lemon R, Ludolph AC, Kiernan MC. Cortical influences drive amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(11):917-924.</Citation></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and toxic Neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(2):364-375.</Citation></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;31(5):635-639.</Citation></Reference><Reference><Citation>Clarke G, Collins RA, Leavitt BR, et al. A one-hit model of cell death in inherited neuronal degenerations. Nature. 2000;406(6792):195-199.</Citation></Reference><Reference><Citation>Hartmaier SL, Rhodes T, Cook SF, et al. Qualitative measures that assess functional disability and quality of life in ALS. Health Qual Life Outcomes. 2022;20(1):12. doi:10.1186/s12955-022-01919-9. PMID: 35062955; PMCID: PMC8781297.</Citation></Reference><Reference><Citation>Crockford C, Newton J, Lonergan K, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91(15):e1370-e1380.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology. 2019;93(10):e984-e994.</Citation></Reference><Reference><Citation>Bersano E, Sarnelli MF, Solara V, et al. Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(5-6):373-379. doi:10.1080/21678421.2020.1771732. Epub 2020 Jun 2.</Citation></Reference><Reference><Citation>Karr JE, Graham RB, Hofer SM, Muniz-Terrera G. When does cognitive decline begin? A systematic review of change point studies on accelerated decline in cognitive and neurological outcomes preceding mild cognitive impairment, dementia, and death. Psychol Aging. 2018;33(2):195-218.</Citation></Reference><Reference><Citation>Alty JE, Clissold BG, McColl CD, Reardon KA, Shiff M, Kempster PA. Longitudinal study of the levodopa motor response in Parkinson's disease: relationship between cognitive decline and motor function. Mov Disord. 2009;24(16):2337-2343.</Citation></Reference><Reference><Citation>Pinto S, de Carvalho M. The R of ALSFRS-R: does it really mirror functional respiratory involvement in amyotrophic lateral sclerosis? Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1-2):120-123. doi:10.3109/21678421.2014.952641. Epub 2014 Sep 10. PMID: 25205208.</Citation></Reference><Reference><Citation>Manera U, Torrieri MC, Moglia C, et al. The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitoring. J Neurol Neurosurg Psychiatry. 2020;91(9):999-1000. doi:10.1136/jnnp-2020-323810. Epub 2020 Jun 30. PMID: 32605931.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>